Why the study?
Does dipyridamole lead to successful pregnancy outcomes in pregnant women with Starr-Edwards prosthetic heart valves?
Does dipyridamole lead to successful pregnancy outcomes in pregnant women with Starr-Edwards prosthetic heart valves?
Dipyridamole treatment during pregnancy resulted in successful outcomes in four women with Starr-Edwards prosthetic heart valves, suggesting a potential alternative to coumarin derivatives.
Should not yet change anticoagulation practice in prosthetic valve pregnancies; leaves open dipyridamole as hypothesis-generating alternative.
Continuing improvements in cardiac surgery and a wider selection of young patients for prosthetic valve replacement mean that an increasing number of women of childbearing age will undergo such procedures and will also subsequently become pregnant. At present, most patients with prosthetic heart valves are treated with anticoagulant drugs for life. The main problem with anticoagulant therapy during pregnancy is fetal and maternal hemorrhage. Congenital anomalies have been described in infants born to mothers treated with coumarin derivatives during the first trimester of pregnancy. Dipyridamole is known to decrease the adhesiveness of platelets or their ability to aggregate. We report the successful outcome of four pregnancies in patients with Starr-Edwards prostheses who were treated with dipyridamole during their pregnancies.
No takes yet. Share an insight, caveat, or question.
Biale et al. (1980) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: